J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?Zacks Investment Research • 07/05/24
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 studyPRNewsWire • 07/02/24
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patientsPRNewsWire • 06/28/24
Lawyers for Johnson & Johnson's Ovarian Cancer Victims React to SCOTUS Decision in PurdueBusiness Wire • 06/27/24
Sell Alert: 3 Dividend Aristocrats That May Kill Your Passive Income SnowballSeeking Alpha • 06/27/24